X-Ray Contrast Media Mechanisms in the Release of Mast Cell Contents: Understanding These Leads to a Treatment for Allergies by Lasser, Elliott C.
Hindawi Publishing Corporation
Journal of Allergy
Volume 2011, Article ID 276258, 5 pages
doi:10.1155/2011/276258
Review Article
X-Ray Contrast Media Mechanismsin the Release of Mast Cell
Contents: UnderstandingTheseLeadsto a Treatmentfor Allergies
ElliottC. Lasser
UCSD Emeritus, USA
Correspondence should be addressed to Elliott C. Lasser, elasser@ucsd.edu
Received 14 May 2011; Revised 15 July 2011; Accepted 16 July 2011
Academic Editor: K. Blaser
Copyright © 2011 Elliott C. Lasser. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A long history of searching for the etiology of X-ray contrast material (CM) reactions has led to the understanding that the CM
do not produce anti-CM antigens. Since CM reactions are anaphylactoid in nature, however, a source for mast cell activation was
sought. This resulted in the ﬁnding that concentrated CM could suppress mast cell activation by attachment to the Fc portion of
IgE and IgG. This is presumed to be a steric hindrance eﬀect. In a study of the eﬀects of CM on BP and a study of the eﬀects of
CM in sensitized rats, it was concluded that less concentrated CM activated mast cells and that this mechanism was best explained
by bridging of adjacent IgE molecules via attachment to their Fc segments. The mast cell release of heparin activating the contact
system, as well as the release of histamine, is believed to be responsible for CM reactions and allergic diatheses.
1. Contrast Media Molecular Structures
Currently all X-ray contrast media (CM) for intravascular
opaciﬁcationaretri-iodinatedbenzenemoietiesthatarefully
s u b s t i t u t e da n do c c u ri ne i t h e ram o n o m e ro rad i m e rf o r m
(Figure 1).
2. The Contact System in CMAnaphylaxis
The contact system is made up of three proteins (Figure 2):
(1) Factor XII, the protein that initiates activation of the
intrinsic coagulation system and can be activated by negative
surfaces in the circulation, (2) prekallikrein, and (3) high
molecular weight kininogen. Activation of Factor XII con-
verts prekallikrein to kallikrein, which converts high molec-
ular kininogen to bradykinin. Bradykinin has essentially the
same physiologic eﬀects as histamine but is signiﬁcantly
more eﬀective on a mole per mole basis. Furthermore,
bradykinin, once formed, can metabolize arachidonic acid
into vasoactive prostaglandins and leukotrienes, all of which
are known to participate in anaphylactic events.
3. Activation of the Contact System and
Negative Surfaces
The elements mentioned above constitute in outline what
is known about some of the important mechanisms that
play a role in anaphylaxis and allergy. Now, it is necessary
to understand what leads up to these events and what can
be done to limit them. Negative surfaces in the circulation
can activate the contact system. In the body negative surfaces
exist in a number of forms. The activation of factor XII
will occur when these surfaces have access to this factor in
suﬃcient concentration. In vitro, we have shown that high
molecular weight dextran sulfate can activate the system
when the temperature is suﬃciently low to inhibit plasma
substances that would otherwise impede this activation [1].
More importantly, we have demonstrated that this process
proceeds more rapidly in atopic or asthmatic individuals
than in individuals without these abnormalities [1]. Asth-
matics can be demonstrated to have higher concentrations
than do nonasthmatics of heparin/heparan sulfate when
these molecules are isolated from their neutralizing sub-
stances [2, 3]( Figure 3).
4.The Role of Heparin-LikeSubstances
What are the sources of these heparin-like molecules? While
heparan sulfate can be found in a number of tissues, includ-
ing endothelial linings, the most obvious source of acute
supply of heparin-like molecules is the mast cell (Figure 4).
When activated, these cells discharge a large number of
substances, including heparin, histamine, tryptase, chymase,2 Journal of Allergy
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Figure 1: Representative current X-ray contrast molecules. Iopamidol is a nonionic monomer. Ioxaglate is an ionic dimer. All current
contrast media have iodide atoms on the 2, 4, and 6 positions on the benzene ring.
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Figure 2: The 3 major proteins of the contact system Factor XII,
Prekallikrein, and high molecular weight kininogen are depicted.
The major role played by the C1 inhibitor is noted. Factor XIIf is a
b r e a k d o w np r o d u c to fF a c t o rX I I .
and ACE and a number of cytokines and chemokines. The
in vivo activation of the mast cells, in turn, results when
IgE attached to speciﬁc receptors on the mast cell surfaces
combine with speciﬁc antigens in the circulation to produce
aggregation of adjacent receptors [4]. (In all our references
to the mast cell in this paper, it is understood that basophils
in the circulation largely exhibit similar characteristics.)
How does heparin/heparan become the negative surface
that will activate the contact system in CM reactions? The
answer to this lies in putting together two counterintuitive
investigations carried out approximately 27 years apart.
5. The Attachment of CM to IgE andIgG
(The Fallacyof AnticipatedData)
In the ﬁrst of the counterintuitive experiments mentioned
above, dogs underwent 27 injections of iothalamate (Conray
60, Mallinckrodt) into the pulmonary artery and blood
samples were collected from a catheter in the left ventricle.
The iothalamate was injected in the same volume (30mL)
in each animal but at diﬀerent injection rates (2mL/sec and
39mL/sec). The left ventricular samples were assayed for
total histamine content over a 5-minute interval. To our
surprise, the maximal histamine blood levels were higher
in 20 of the 27 injections when the CM was injected more
slowly [6]. In the second of the two experiments, RBC
hemagglutination inhibition studies were carried out with
several stereotypical CM molecules. The CM used were the
same concentrations carried in the commercial vials. (141–
320mgI/mL). In the study, several diﬀerent antigens were
used. While all the tested CM interfered with the antibody-
antigen reactivity at diﬀerent concentrations, the ionic and
nonionic dimers and nonionic monomers accomplished this
at lesser concentrations of CM than did the ionic monomers
[7]( Figure 1). This was counterintuitive, since the inter-
ference implied that the CM attached to the antibodies to
the exclusion of the speciﬁc antigens to these antibodies.
Attachment to the antibody by the CM was reasoned to
be at the basis of IgE activation of mast cells as was the
case with all antigens. In the case of true antigens, the best
attachment to the immunoglobulin (at Fab) produces theJournal of Allergy 3
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Figure 3: The mast cell dynamics are depicted. Mast cell release
occurs when the IgE receptors aggregate and come closer to one
another. IgE on the cell is shown to be bridged by antigens (red
arrows) binding to the Fab, segment, resulting in mast cell release.
Release also occurs in the presence of antigen attachment plus low
concentration CM attachment (blue wave forms). Finally, release
occurs when there is low CM concentration attachment alone.
High concentrations of CM are thought to act by steric hindrance
alone and/or by sterically dislodging bound true antigens. The
red dashes represent points of possible corticosteroid inhibitory
eﬀect.
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Figure 4: In this study, 6 patients were subjected to inhalational
challenge with antigens to which they were known to be sensitive
[5]. Simultaneous samples of blood were drawn from the brachial
artery and from the antecubital vein. A representative patient is
shown here. EHM is endogenous heparin-like material, measured
with a functional anti-Xa assay after removing neutralizing sub-
stances from the heparin by adding low molecular weight dextran
sulfate. After the 1:1000 spore challenge, there is an immediate
rise in both the EHM material produced by exposing plasma to
low molecular weight dextran (red line) and the material with
heparin neutralizing substances intact when water, rather than
dextran sulfate, was added to the plasma (blue line). A concurrent
fall in FEV1 occurs along with the rise in heparin levels when the
1:1,000 antigen was inhaled. Similar ﬁndings occurred in 3 of the 6
patients.
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Figure 5: Rats sensitized to ovalbumin and then challenged with
ovalbumin, displayed signiﬁcantly diﬀerent BP patterns in the
presence of either Hexabrix or normal saline. With Hexabrix,
whether given 45 minutes earlier, at the time of antigen challenge,
or at the nadir of BP levels, there was an abrupt upward swing in
BP levels in contradistinction to the prolonged fall in the presence
of the saline.
most activation of the mast cell [7]. In the hemagglutination
inhibition study, however, the best attachment was to the
CM most unlikely to clinically activate the IgE on mast cells.
Then, remembering the puzzling histamine release results in
thestudydone27yearsearlier,arealizationdawnedonus.In
the earlier experiment, we were looking at a SUPPRESSION
of IgE activated mast cell activity by the faster injection,
not the expected ACTIVATION! The target tissue in this
experiment was the lung, and the histamine release from
pulmonary mast cells was detected in the heart so that the
release was modulated by a high concentration of CM not
usually available in other peripheral target tissues.
We also realized that the CM must attach to the Fc
(constant) portion of the immunoglobulins and not the
Fab (variable) portion where most antigens attached, since
the attachment occurred with multiple antigens and was
therefore nonspeciﬁc. In a limited subsection of this study,
we found that CM could apparently detach speciﬁc antigens
if the antigen-antibody complex were shaken for a few
minutes before the CM was added.
6. CM Attachment to the Immunoglobulins
A number of studies to substantiate the foregoing were then
carried out. The ﬁrst was that the CM, attaching to the cons-
tant portion of the immunoglobulin, then had the potential
to interfere with attachment of speciﬁc antigens to the
variable part of the immunoglobulin. This was borne out in
follow-up studies [8]. Further, we must come to terms with
the fact that in vivo and in vitro, CM, in fact, could activate
as well as suppress mast cell activity. To accommodate this
fact,itwasnecessarytopostulatethatatlesserconcentrations
attachment of CM to Fc portions of immunoglobulins may
activate IgE and lead to the adverse reactions sometimes
associated with intravascular CM injections, while at higher
concentrations, CM will inhibit activation (Figure 3). On a4 Journal of Allergy
theoretical basis, this now seemed reasonable, since all the
CM are known to show some degree of aggregation at hig-
her concentrations (all the CM have a calculated osmo-
lality that is higher than their experimental values) [9]. It
seems probable that at the higher concentrations the CM
aggregation produces a steric hindrance eﬀect that limits
the necessary receptor aggregation for mast cell activation.
The other ﬁnding that should be emphasized is that CM are
completely nonspeciﬁc; that is, they can interfere with any
antigen binding to IgG or IgE, and thus merit consideration
in any circumstance where CM are present and antigen-
antibody reactions take place.
7. Where and Why Do the CM Bind to IgE?
In our studies that showed that all of the CM could attach to
the Fc portion of immunoglobulins and that the ionic and
nonionic dimers bound at lesser concentrations than the
monomers, it must be assumed that it is the iodine atoms on
the benzene rings that are mainly responsible for the binding
to the Fc segments (Figures 1 and 3). This assumption is
justiﬁed,sincetheiodinesaretheonlycommonalityamongst
the various CM, there are more iodines available on the
dimer than on the monomer, and less molar concentration
of the dimer is necessary to inhibit antigen attachment on
the RBC hemagglutination assay. Finally, it should be noted
that iodine has been shown to bind to some carbohydrate
structures although this may be speciﬁc for amylose and
elementary iodine [10]. Central carbohydrates are present
on the Fc structure of these immunoglobulins, and while we
have no proof, these would seem to be the most obvious site
for these bindings.
8.F urth e rDatainP r oo f
To substantiate the considerations put forward in the above
paragraphs, a number of studies were done: PCA (passive
cutaneous anaphylaxis) rat study done with an ionic mono-
mer, meglumine/sodium diatrizoate (Angiovist 370, Bracco
Diagnostics), showed an inhibition of immune mediated
permeability in rough proportion to the CM used [8]. In a
study of BP changes in rats injected IV with various CM, the
CM demonstrating the poorest (least) binding to antibodies
in the RBC hemagglutination inhibition tests (the ionic
monomers) showed a drop in BP on injection proportionate
to the volumes injected [8]. The CM with better binding
(the ionic and nonionic dimers) showed an increase in B.P.
on injection, again in proportion to the volumes injected
[8]. Injections of 2 strains of rats with diphenhydramine,
(Benadryl, Mc Neil-PPC) at a dose of 5mg/kg also produced
a rise in BP as did injections of L-Name, an inhibitor of nitric
oxide [8]. Sensitized rats challenged with the sensitizing
antigen and then injected with either a dimer CM or saline
showed that the saline injection continued the fall in BP
occasioned by the challenge, while the CM produced an
upward change in the BP [8]. (Figure 5). These studies were
interpreted to show that the CM with better (increased)
binding to the Fc portions of IgE inhibited mast cell activity,
and thereby diminished the resultant basal blood histamine
and NO levels producing higher BP.
9. Test of the Concepts inHumans
To test our assumptions that the construct that we had put
together would have a role in human allergy, we arranged
for a 20-person study of allergic rhinitis with ioxaglate
320 (Hexabrix, Guerbet) versus placebo, in individuals with
tested sensitivities to the applied antigens [11]. This was a
double-blinded crossover study, and the antigen was applied
on pads to the nasal mucosa 20 minutes after 2 drops of
ioxaglate 320 or saline were dropped into the nostril. In
these studies, the patients score the usual symptoms of nasal
allergy on a 1+ to 3+ scale. Without going into details, the
application of the CM produced fewer symptoms than the
placeboinallevaluations.Signiﬁcantdiﬀerences(t-test)were
found for “sneezing” (P = 0.018) and “runny nose” (P =
0.048) and the combination of “sneezing”, “runny nose” and
“itching” was (P = 0.06).
10. Application versusCirculatingAnti-IgE
All of these ﬁndings indicate that the CM when applied
topically act on peripheral targets in the same fashion as do
injections of the monoclonal humanized anti-IgE antibody
omalizumab(Xolair,Genentech/Novartis)[12].Bothbindto
the Fc portion of antibodies. The action of the CM, however,
is immediate and probably acts on both mast cells seated IgE
as well as IgE in the local circulation and interstitium, since
the eﬀects are abrupt, while the production and action of the
monoclonal antibody takes place only over time and is said
to be precluded from activity on IgE already seated on mast
cells. Although we have no proof of this, it seems likely that
CM attachment to local interstitial IgE, like Xolair, will down
regulate the density of the IgE receptor on regional mast cells
if applied over time.
Since “application” of the CM easily provides the dose
and concentration necessary (about 1/250 of common intra-
vascular dosages) for inhibition of all local mast cell activat-
ing processes, it is signiﬁcant to consider the various possible
clinical applications which include the nose (allergic rhini-
tis), the eye (allergic conjunctivitis), the bronchi (asthma),
the skin (atopic dermatitis), the esophagus (eosinophilic
esophagitis), and possibly intra-articular spaces, the colon,
and any other space open to installation or catheterization
in which the mast cells are believed to play a signiﬁcant
role.
11.Technical Note
As an additional note, it must be realized that the potential
of CM to inhibit competing antigens for attachment to
antibodies makes it important to be sure that in the presence
of CM in the circulation, the results of assays that depend
on correct antigen-antibody dynamics, such as ELISA, are
regarded with suspicion. This was ﬁrst noted in a Japanese
study, where tumor antigens were assayed and found to be
less than expected quantitatively. It was noted by the authors
that this occurred in several assays, where the patients
had recently received intravascular CM and the association
was made, but the explanation for the association was not
forthcoming [5].Journal of Allergy 5
12. Conclusions
We are aware now that CM have potential pharmacologic
applications beyond conventional opaciﬁcation in X-ray
studies. They are unique for small molecules in that they will
inhibit ANY antigen-antibody reaction. Principles gleaned
from research in CM physiology have suggested to us a
new and completely unique approach to the treatment of
hypersensitivity reactions. The abrupt inhibition of release
of heparin and other mast cell products by suﬃciently con-
centrated CM applied topically, and the profound inhibition
of contact system activation is the key to this.
While our research to date highlights CM inhibition of
mast cells and symptoms of acute allergic rhinitis, we are
aware that other cellular eﬀectors including dendritic cells
and monocytes, which are essential in the pathogenesis of
chronic allergic rhinitis, atopic dermatitis, and asthma, also
respond to upregulated IgE receptors that potentially may
be inhibited in a similar fashion. In this regard, we have
had encouraging results in treating a mouse model of atopic
eczema, and expect similar results in humans.
It is also possible that CM injected intravascularly in
suﬃcient concentrations to bind to IgE in the circulation
or on mast cells with the potential to compete with
sensitizing antigens can be considered in the therapy of
severe anaphylaxis. We have already demonstrated that this
is possible in rats (Figure 5), and there is some evidence
that the injection of epinephrine in these circumstances
is not always accomplishing what is expected [13]. This
approach, however, would entail considerable additional
research, since suboptimal concentrations could activate
mast cell anaphylaxis.
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